Press release 02/2014

Success at the European Society of Contraception (ESC) Conference 2014 in Lisbon

strong interest among family planning providers from nearly 30 countries


Mörfelden-Walldorf, June 2014: KESSEL medintim GmbH presented the Caya® contoured diaphragm and shared first-year market experience from Europe to enthusiastic audiences at the ESC Conference in Lisbon at the end of May 2014. Almost 500 family planning providers, policymakers, and researchers from nearly 30 countries requested additional information about the product. When Caya® was approved in Europe 2013, it was the first barrier contraceptive approved in more than a decade. The introduction of Caya® coincides with increased attention to nonhormonal methods as evidence suggests that some women who do not want to become pregnant are not using existing methods because they do not meet their needs.


Caya® is a “one size fits most women” reusable contraceptive diaphragm. It was developed by a nonprofit international health organization and its research partners to expand women’s options for nonhormonal barrier contraception. Caya® was developed through a user-centered process that included feedback from women, men and family planning providers from four countries to refine the design. This resulted in innovative features that make the product easy to use and comfortable for both partners. The single-size design should be easy to supply and provide. No pelvic exam is required to assess diaphragm size. The single-size diaphragm is made of thin, durable silicone. It is reusable for up to two years, which will add to its cost effectiveness.


The KESSEL medintim GmbH in Walldorf near Frankfurt/Main is the license holder and manufacturer of the single-sized contraceptive diaphragm. Through distributor partnerships, the Caya® diaphragm is being sold in 14 European countries and Canada. Today, already around 15,000 women have used Caya® worldwide.


During the past year, Kessel has launched the Caya® diaphragm in Europe and Canada. Kessel is working with qualified distributors to expand the availability of the Caya® contoured diaphragm to new markets. Regulatory applications are in process in several countries, including the United States. Partner organizations are working to build evidence for how to introduce the Caya® diaphragm in low and middle income countries where diaphragms have not been available in recent decades.


Additional clinical studies also are planned to evaluate the feasibility of using the Caya® diaphragm as a reusable delivery system for microbicide gel. Microbicides are products being developed to protect from HIV infection. Once an effective microbicide gel is approved, using the microbicide gel along with the Caya® diaphragm could protect from both unintended pregnancy and HIV or other infections.

Mörfelden-Walldorf, 03 June 2014
Contact:
KESSEL medintim GmbH
Martin Kessel
Kelsterbacher Str.28
64546 Mörfelden-Walldorf
Germany
Tel.: +49(0)6105 - 20 37 20
E-mail: kessel@medintim.de